SCHEMBL162918

SCHEMBL162918

CCNC(=O)c1nccc([O])n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.39
RIPK1 Q13546 1/20 0.38
HIF1A Q16665 1/20 0.38
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KDM4E B2RXH2 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
HPGDS O60760 1/20 0.37
CHIA Q9BZP6 1/20 0.37
CA1 P00915 1/20 0.36
GAA P10253 1/20 0.36
CA9 Q16790 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
P2RX7 Q99572 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162211 0.87 HIF1A (0.42) RIPK1HIF1AKDM4EL3MBTL1LMNA
SCHEMBL159955 0.84 HTT (0.49) HIF1AKDM4EL3MBTL1LMNAHTT
SCHEMBL160244 0.82 KMT2A (0.45) HDAC4KDM4EHTTGAANPSR1
SCHEMBL162373 0.80 PLK1 (0.39) CNR1RIPK1HDAC6KDM4EHTT
SCHEMBL25982928 0.79 CNR1 (0.37) CNR1RIPK1HIF1AKDM4EL3MBTL1
SCHEMBL160275 0.78 MEN1 (0.45) KDM4EL3MBTL1HTTNPC1KMT2A
SCHEMBL13359252 0.77 P2RX7 (0.59) CNR1RIPK1KDM4EL3MBTL1LMNA
SCHEMBL24921759 0.76 ADORA2A (0.40) CNR1RIPK1HIF1AKDM4EL3MBTL1
SCHEMBL163732 0.76 FDPS (0.41) CNR1RIPK1KDM4EHPGDSNPC1
SCHEMBL161652 0.76 SMN1; SMN2 (0.39) RIPK1KDM4EL3MBTL1LMNAHPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 CNR1 3934/4885RIPK1 2810/4885HIF1A 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.